Rabies

Veterinary Infectious Disease Diagnostics Global Market Report 2022: Increasing Incidence of Transboundary and Zoonotic Diseases Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 4, 2022
Veterinary, Health, PETS, RT, Dog, Incidence, Human, World Health Organization, WHO, Asia-Pacific, World, Death, Gold, Mutation, Growth, Infection, Animal, Acquisition, Rabies, Vaccine, Zoonosis

The "Veterinary Infectious Disease Diagnostics Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Veterinary Infectious Disease Diagnostics Global Market Report 2022" report has been added to ResearchAndMarkets.com's offering.
  • The regions covered in the veterinary infectious disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
  • The increasing incidence of transboundary and zoonotic diseases such as rabies is expected to propel the growth of the veterinary infectious disease diagnostics market going forward.
  • Therefore, the increasing incidence of transboundary and zoonotic diseases is driving the growth of the veterinary infectious disease diagnostics market.

Dyadic to Present Disruptive C1 Technology at World Vaccine Congress Europe Announcing Expansion of Influenza Pipeline with Enhanced Efficacy Potential

Retrieved on: 
Tuesday, October 4, 2022
Congress, Fira (Barcelona Metro), Vaccine, Securities Exchange Act of 1934, Veterinary medicine, Food, NASDAQ, Livestock, Achievement, Dyadic, Palau, Omicron, SEC, Form 10-K, Clinical trial, Interest, National Food Security Act, 2013, Health, RBD, Virus, Protein, Nano, Antibody, COVID-19, University of Veterinary Medicine Hanover, Nanoparticle, University, China Biologic Products, Rabies, Securities Act of 1933, GLOBE, Fine chemical, C1

The presentation will highlight significant achievements, including:

Key Points: 
  • The presentation will highlight significant achievements, including:
    Successful expression of Omicron BA.5 RBD and gRBD ferritin nano particle antigens including Wuhan and Omicron BA.2 from C1 cells.
  • Nanoparticle antigens have demonstrated the potential to lead to broader and longer lasting protection against a number of viruses, including Covid-19 variants of concern.
  • Enhanced influenza vaccine efficacy potential and productivity data of C1 expressed antigens, expanding our pipeline to help address seasonal and pandemic flu markets.
  • Dyadic assumes no obligation to update publicly any such forward-looking statements, whether because of new information, future events or otherwise.

BOEHRINGER INGELHEIM DONATES NEARLY 100,000 PET VACCINE DOSES TO HELP ELIMINATE RABIES AROUND THE WORLD WITH RELAUNCH OF SHOTS FOR GOOD(SM) INITIATIVE

Retrieved on: 
Wednesday, September 28, 2022
Health, Charity Navigator, Human, Risk, Akwa Ibom State Association of Nigeria, USA Inc., Vaccination, United Nations, Organization, Farmer, Veterinarian, World Rabies Day, Program, Global Alliance for Rabies Control, Boehringer Ingelheim Animal Health, Rabies, Global Alliance, Vaccine, Dog, Greater good, Death, Boehringer Ingelheim, PETS, Awareness, Animal, Shots, Good, International, Charitable organization, First Nations in Ontario, Livestock, Medical device

DULUTH, Ga., Sept. 28, 2022 /PRNewswire/ -- Boehringer Ingelheim, a global leader in veterinary rabies vaccines, has expanded its commitment to help prevent rabies in dogs by donating nearly 100,000 doses of rabies vaccine. The donation is part of the relaunched SHOTS FOR GOOD℠ program and will be used on tribal lands and in underserved communities across the United States.

Key Points: 
  • Rabies is present on all continents, except Antarctica, with over 95% of human deaths occurring in the Asia and Africa regionsiii.
  • Dogs are the main source of human rabies deaths, contributing up to 99% of all rabies transmissions to humansiv.
  • "The generous vaccine donations from Boehringer Ingelheim Animal Health and the Shots for Good initiative helps to protect pets while making this important effort possible."
  • Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals.

GlobalVetLink Announces Addition of Equine Rabies Vaccination Certificates on World Rabies Day

Retrieved on: 
Wednesday, September 28, 2022
World Rabies Day, Health, Safety, Veterinarian, Product management, Horse, Trade reporting and compliance engine, Vaccination, USDA, Immunity, Patient, Rabies, Compliance, Documentation, Animal, Multimedia, International, Software as a service, Dog, View, Vaccine, AMES

AMES, Iowa, Sept. 28, 2022 /PRNewswire/ -- September 28th is recognized as World Rabies Day and GlobalVetLink is excited to announce the timely addition of Equine Rabies Vaccination Certificates to the GlobalVetLink Compliance Assistant platform. This product enhancement provides a simple solution for equine veterinarians issuing rabies vaccination certificates to their equine clients.

Key Points: 
  • AMES, Iowa, Sept. 28, 2022 /PRNewswire/ -- September 28th is recognized as World Rabies Day and GlobalVetLink is excited to announce the timely addition of Equine Rabies Vaccination Certificates to the GlobalVetLink Compliance Assistant platform.
  • This product enhancement provides a simple solution for equine veterinarians issuing rabies vaccination certificates to their equine clients.
  • The GVL Compliance Assistant platform now streamlines the process for issuing equine rabies vaccination certificates, further simplifying a veterinarian's day to day activities.
  • "We are excited to announce the addition of Equine Rabies Vaccination Certificates to the GVL Compliance Assistant platform," said Stacey Noe, Director of Product Management at GlobalVetLink.

2022 World Rabies Day webinar explores challenges and opportunities for remote Canadian communities tackling rabies

Retrieved on: 
Wednesday, September 28, 2022
World Rabies Day, Health, Risk, Veterinarian, Environment, Rabies, CEO, Vaccine, Public health, Veterinary biologic, GLOBE, PETS, Awareness, Red fox, Animal, First Nations, Dog

Toronto, Ontario, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is pleased to host the second annual World Rabies Day webinar as a part of World Rabies Day 2022.

Key Points: 
  • Toronto, Ontario, Sept. 28, 2022 (GLOBE NEWSWIRE) -- The Canadian Animal Health Institute (CAHI) is pleased to host the second annual World Rabies Day webinar as a part of World Rabies Day 2022.
  • This World Rabies Day event aims to support the development of both animal health and public health in Canadas remote northern communities by building increased awareness of the challenges and opportunities across Canadas unique geography.
  • Made possible by the generous support of Zoetis Canada Inc. and Boehringer Ingelheim Animal Health Canada Inc., the World Rabies Day 2022 webinar will be hosted by CAHI later today, from 12:00 1:00pm EDT.
  • For webinar information and free registration, see https://live.webcastcanada.ca/go/rabies-english
    Established in 1968, CAHI is the trusted, science-based voice of the Canadian animal health industry.

Curative Biotechnology Announces Intent to Uplist to NYSE American Exchange

Retrieved on: 
Tuesday, September 27, 2022
Neuro, Securities Exchange Act of 1934, CD56, NYSE, Infection, Sale, Securities Act of 1933, U.S. Securities and Exchange Commission, Company, NYSE American, Degenerative disease, Judgement, Review, Neoplasm, Historical annual reformulations of the influenza vaccine, CUSIP, Rabies, Metformin, OTC, Vaccine, Greenbriar Capital Corp, OTC Markets Group, Form, AMD, Prospectus, GLOBE, SEC, Biotechnology, Security (finance)

The Company has applied to list its common stock on the NYSE American under the symbol CUBT.

Key Points: 
  • The Company has applied to list its common stock on the NYSE American under the symbol CUBT.
  • 333-264339) previously filed with the U.S. Securities and Exchange Commission (SEC), which has not yet become effective.
  • The offering is expected to close on or about September 30th, 2022, and to begin trading on the NYSE American on or about October 3rd, 2022.
  • Curative Biotechnology, Inc. (Curative Biotech) is a development stage biomedical company focused on novel therapies for rare diseases.

Dr. Jeanne Bolger to chair Board of Directors of Belgium-based vaccine technology company AstriVax

Retrieved on: 
Monday, September 26, 2022
Hepatitis, BNP Paribas Fortis, Vaccine, Biohub, Ackermans & van Haaren, GlaxoSmithKline, Johnson & Johnson, Investment, Rabies, CEO, Technology, Board of directors, Leadership, MB, Board, Infection, Pharmaceutical industry

Dr Jeanne Bolger brings over 35 years of management experience in the pharmaceutical industry to the new Belgium-based vaccine technology company.

Key Points: 
  • Dr Jeanne Bolger brings over 35 years of management experience in the pharmaceutical industry to the new Belgium-based vaccine technology company.
  • With this seed capital and the support of Dr Bolger, AstriVax will continue to build its innovative plug-and-play vaccine platform and bring its first vaccines to the clinical development stage.
  • Leuven, Belgium, 26 September 2022 AstriVax has announced that Dr Jeanne Bolger will chair its Board of Directors as non-executive independent director.
  • As the new Chair of the AstriVax Board, doctor and biotech investor Jeanne Bolger brings extensive experience in the pharmaceutical industry, with management roles across R&D, commercial and business development, and venture investments.

AIM Vaccine Announces Proposed Listing on the Main Board of SEHK

Retrieved on: 
Friday, September 23, 2022
Global, Safety, IPV, Efficiency, CIC, National Medical Products Administration, RNA transfection, HFRS, HAV, Goldman Sachs, Industry, China International Capital Corporation, Stock exchange, Clinical trial, Mumps, Technology, CDC, Meningococcal disease, Vaccine, US, HPV, Research, International, SEHK, COVID-19, Food, Company, Rabies, NDA, Omicron, Science, Exploration, NMPA, Globe, COVID-19 vaccine, AIM, Culture, L.L.C, National, CTA, Honesty, HBV, CMOS, Public health, Coronavirus, Record, Marketing, GMP, Motherboard, Health, The Group, Program, 2000 Simpsonwood CDC conference, Infection, Pharmaceutical industry, Property management, PRC, Group, Limited

According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.

Key Points: 
  • According to CIC, AIM Vaccine is the only China-based vaccine player that has all five proven human vaccine platform technologies worldwide, namely bacterial vaccine technologies, viral vaccine technologies, genetically engineered vaccine technologies, combination vaccine technologies and mRNA vaccine technologies, with at least one approved product or one vaccine candidate at CTA or clinical stages under each platform.
  • AIM Vaccine currently commercializes eight vaccine products against six disease areas, of which the HBV vaccines and human rabies vaccine are its market-leading key commercialized vaccine products.
  • AIM Vaccine acquired Rong'an Bio, AIM Honesty, AIM Kanghuai and AIM Weixin between 2015 and 2017, together with their vaccine products against human rabies, HBV, HAV, mumps and HFRS.
  • AIM Vaccine has leading scientists joining or collaborating with AIM Vaccine to support the Group's vaccine development and manufacturing.

Veterinary Pain Management Market worth $2.5 billion by 2027 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Thursday, September 22, 2022
Knowledge, Chanelle Pharma Novice Hurdle, GEM, Adoption, Temperature, Lists of diseases, Brain, Dechra Pharmaceuticals, Prevalence, Nonsteroidal anti-inflammatory drug, Poultry, Inactivation, Overweight, Merck & Co., Population, Osteoarthritis, USD, Cancer, Intelligence, Pain, Rabies, SME, Arthralgia, Tissue, Livestock, Research, Pain management, PETS, CAGR, Vaccine, Marketing, Aquaculture, Toxoid, Coccidiosis, Brucellosis, Technology, Disease

In this report, the veterinary pain management market has been segmented by product, application, animal type, end user, and region.

Key Points: 
  • In this report, the veterinary pain management market has been segmented by product, application, animal type, end user, and region.
  • In 2021, the NSAIDs segment accounted for largest share of the veterinary pain management drugs market.
  • The veterinary pain management drugs market is segment into oral, parenteral, and topical on the basis of route of administration.
  • Based on applications, the veterinary pain management market is segmented into joint pain, post-operative pain, cancer, and other applications.

Bavarian Nordic Awarded Ten-Year Contract Amendment valued up to USD 434 million for the Supply of Smallpox and Monkeypox Vaccine to Canada

Retrieved on: 
Tuesday, September 20, 2022
Smallpox vaccine, Public Health Agency of Canada, PHAC, COVID-19, Tick-borne encephalitis, FDA, Food, DND, Vaccination, European Commission, Janssen Pharmaceuticals, Population, Forward-looking statement, Government, USD, Regulation of tobacco by the U.S. Food and Drug Administration, Johnson & Johnson, Rabies, Public Health Agency, Health Canada, Vaccine, Immunodeficiency, Goal, National security, OMX, Smallpox, Royal commission, Monkeypox, Immune system, Modified vaccinia Ankara, Cryptocurrency, Bavarian Nordic

This extends the USD 56 million contract awarded in June 2022 to a total value of up to USD 470 million.

Key Points: 
  • This extends the USD 56 million contract awarded in June 2022 to a total value of up to USD 470 million.
  • Furthermore, a new multi-year contract has been signed with Canadas Department of National Defence (DND) at a value of USD 2 million, in addition to USD 18 million in contract options.
  • Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: With foresight and prioritization, Canada has shown the way to building a robust preparedness for its population.
  • The vaccine is also approved for protection against smallpox and monkeypox in Canada, and as a smallpox vaccine in Europe.